Five Prime Therapeutics (FPRX) to Release Quarterly Earnings on Wednesday

Five Prime Therapeutics (NASDAQ:FPRX) is set to announce its earnings results after the market closes on Wednesday, August 8th. Analysts expect the company to announce earnings of ($1.25) per share for the quarter.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.08). Five Prime Therapeutics had a negative net margin of 221.74% and a negative return on equity of 44.36%. The business had revenue of $32.49 million during the quarter, compared to analysts’ expectations of $37.50 million. On average, analysts expect Five Prime Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of Five Prime Therapeutics opened at $15.19 on Monday, Marketbeat reports. Five Prime Therapeutics has a 52 week low of $14.46 and a 52 week high of $48.87. The firm has a market capitalization of $534.83 million, a PE ratio of -2.82 and a beta of 3.32.

A number of equities analysts have recently commented on the stock. ValuEngine downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 28th. BidaskClub downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Raymond James assumed coverage on shares of Five Prime Therapeutics in a research note on Thursday, June 28th. They issued a “market perform” rating on the stock. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Five Prime Therapeutics in a research note on Friday, June 15th. They issued a “neutral” rating and a $19.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. Five Prime Therapeutics currently has an average rating of “Hold” and an average price target of $33.00.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Article: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit